TCR2 Therapeutics Inc.
TCRR · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $29,265 | $25,736 | $24,791 | $25,767 |
| G&A Expenses | $8,201 | $5,803 | $6,312 | $6,004 |
| SG&A Expenses | $8,201 | $5,803 | $6,312 | $6,004 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $37,466 | $31,539 | $31,103 | $31,771 |
| Operating Income | -$41,507 | -$61,422 | -$31,103 | -$31,771 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,111 | $1,013 | $510 | $298 |
| Pre-Tax Income | -$40,396 | -$60,409 | -$30,593 | -$31,473 |
| Tax Expense | $3 | $96 | $1 | $128 |
| Net Income | -$40,399 | -$60,505 | -$30,594 | -$31,601 |
| % Margin | – | – | – | – |
| EPS | -1.03 | -1.56 | -0.79 | -0.82 |
| % Growth | 34% | -97.5% | 3.7% | – |
| EPS Diluted | -1.03 | -1.56 | -0.79 | -0.82 |
| Weighted Avg Shares Out | 39,221 | 38,808 | 38,621 | 38,567 |
| Weighted Avg Shares Out Dil | 39,221 | 38,808 | 38,621 | 38,567 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,111 | $1,013 | $510 | $298 |
| Interest Expense | $6,971 | $0 | $0 | $298 |
| Depreciation & Amortization | $8,697 | $59,766 | $890 | $704 |
| EBITDA | -$32,810 | -$1,656 | -$30,213 | -$30,471 |
| % Margin | – | – | – | – |